Teledoc (TDOC) Gets a $7 Price Target From Barclays: Can It Double From Recent Lows?

Core Viewpoint - Teladoc Health (TDOC) has shown a recovery from its lows, but the stock is still under pressure with a significant decline over the longer term [2][3] Stock Performance - Shares increased by 1.37% over the past week and 3.83% over the past month, but are down 21.21% year-to-date and nearly 36% over the past year [2] - The stock is currently priced at $5.57, significantly below its 52-week high of $9.77, and has experienced a five-year decline of 96.85% from a peak of approximately $176.89 [3] Analyst Ratings - The Street consensus target for TDOC is $7.12, with 21 out of 27 analysts rating the stock as a Hold [3] - Barclays has reduced its price target for TDOC to $7 from $8.50, maintaining an Equal Weight rating after discussions with management [4] Revenue and Growth Drivers - Teladoc generated annualized insurance revenue of $40 million in Q4 2025, with a target of $75 million to $90 million for 2026 as BetterHelp transitions to insurance-based delivery [7][8] - International revenue increased by 19% year-over-year to $125 million in Q4 2025, accounting for nearly 24% of total segment revenue for the full year [8] - Adjusted EBITDA improved by 12% to $83.8 million in Q4, and the company generated $167 million in free cash flow for the full year 2025 [8] Business Transition - BetterHelp's revenue fell by 7% year-over-year in Q4 2025, with guidance for a further decline of 0.5% to 7.0% in 2026 as the segment shifts towards insurance-based delivery [5][6] - The company's recovery hinges on growing BetterHelp's insurance business faster than the decline in its direct-pay business, with a market capitalization target of approximately $1.25 billion to reach the Barclays price target by the end of 2026 [7]